Simon J. Ogrodnik

Longitudinal therapy monitoring of ALK-positive lung cancer by combined copy number and targeted mutation profiling of cell-free DNA

Steffen Dietz, Petros Christopoulos, Zhao Yuan et al. · EBioMedicine · 2020 · 46 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival

Petros Christopoulos, Steffen Dietz, Martina Kirchner et al. · Cancers · 2019 · 42 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis

Arlou Kristina Angeles, Petros Christopoulos, Zhao Yuan et al. · npj Precision Oncology · 2021 · 35 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in <i>KLC1–ALK</i>-rearranged lung cancer

Steffen Dietz, Petros Christopoulos, Lisa Gu et al. · Molecular Case Studies · 2019 · 23 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Low-coverage whole genome sequencing of cell-free DNA to predict and track immunotherapy response in advanced non-small cell lung cancer

Florian Janke, Arlou Kristina Angeles, Anja Lisa Riediger et al. · Journal of Experimental & Clinical Cancer Research · 2025 · 11 citations · Full text

Medicine, Genetics, Oncology +17